(Q54531262)

English

Economic evaluation of the 70-gene prognosis-signature (MammaPrint®) in hormone receptor-positive, lymph node-negative, human epidermal growth factor receptor type 2-negative early stage breast cancer in Japan.

scientific article published in June 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

31 May 2018

http://europepmc.org/abstract/MED/22315134

Economic evaluation of the 70-gene prognosis-signature (MammaPrint®) in hormone receptor-positive, lymph node-negative, human epidermal growth factor receptor type 2-negative early stage breast cancer in Japan. (English)

1 reference

Europe PubMed Central

31 May 2018

http://europepmc.org/abstract/MED/22315134

0 references

4

object named as

Masakazu Toi

1 reference

Europe PubMed Central

31 May 2018

http://europepmc.org/abstract/MED/22315134

author name string

Masahide Kondo

1

1 reference

Europe PubMed Central

31 May 2018

http://europepmc.org/abstract/MED/22315134

Shu-Ling Hoshi

2

1 reference

Europe PubMed Central

31 May 2018

http://europepmc.org/abstract/MED/22315134

Hiroshi Ishiguro

3

1 reference

Europe PubMed Central

31 May 2018

http://europepmc.org/abstract/MED/22315134

language of work or name

0 references

publication date

1 June 2012

1 reference

Europe PubMed Central

31 May 2018

http://europepmc.org/abstract/MED/22315134

Breast Cancer Research and Treatment

1 reference

Europe PubMed Central

31 May 2018

http://europepmc.org/abstract/MED/22315134

133

1 reference

Europe PubMed Central

31 May 2018

http://europepmc.org/abstract/MED/22315134

2

1 reference

Europe PubMed Central

31 May 2018

http://europepmc.org/abstract/MED/22315134

759-768

1 reference

Europe PubMed Central

31 May 2018

http://europepmc.org/abstract/MED/22315134

https://scigraph.springernature.com/pub.10.1007/s10549-012-1979-7

0 references

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1979-7

21 January 2018

Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1979-7

21 January 2018

Gene expression profiling predicts clinical outcome of breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1979-7

21 January 2018

A gene-expression signature as a predictor of survival in breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1979-7

21 January 2018

Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1979-7

21 January 2018

Clinical utility of the 70-gene MammaPrint profile in a Japanese population.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1979-7

21 January 2018

Gene expression profiling: decoding breast cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1979-7

21 January 2018

Economic evaluation of 21-gene reverse transcriptase-polymerase chain reaction assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer in Japan

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1979-7

21 January 2018

HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1979-7

21 January 2018

Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1979-7

21 January 2018

Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer. A decision-analysis model

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1979-7

21 January 2018

Systematic overview of cost-utility assessments in oncology

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1979-7

21 January 2018

Polychemotherapy for early breast cancer: an overview of the randomised clinical trials with quality-adjusted survival analysis

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1979-7

21 January 2018

Interim analysis of a phase II trial of cyclophosphamide, epirubicin and 5-fluorouracil (CEF) followed by docetaxel as preoperative chemotherapy for early stage breast carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1979-7

21 January 2018

Does granulocyte colony-stimulating factor worsen anemia in early breast cancer patients treated with epirubicin and cyclophosphamide?

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1979-7

21 January 2018

Economic evaluation of chemoprevention of breast cancer with tamoxifen and raloxifene among high-risk women in Japan

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1979-7

21 January 2018

Transferability of health technology assessments and economic evaluations: a systematic review of approaches for assessment and application

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1979-7

21 January 2018

Economic evaluation of intensive chemotherapy with prophylactic granulocyte colony-stimulating factor for patients with high-risk early breast cancer in Japan.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1979-7

21 January 2018

Current and emerging biomarkers in breast cancer: prognosis and prediction

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1979-7

21 January 2018

The model-based cost-effectiveness analysis of 1-year adjuvant trastuzumab treatment: based on 2-year follow-up HERA trial data.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1979-7

21 January 2018

International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness?

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1979-7

21 January 2018

Identifiers

10.1007/S10549-012-1979-7

1 reference

Europe PubMed Central

31 May 2018

http://europepmc.org/abstract/MED/22315134

1 reference

Europe PubMed Central

31 May 2018

http://europepmc.org/abstract/MED/22315134

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54531262&oldid=1756358729"